SOUTH SAN FRANCISCO, Calif., March 27, 2017 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM) today announced that Nicolas Barthelemy and Dr. Carlos Paya have been appointed to its Board of Directors.
Barthelemy brings over 25 years of health care industry experience to the Fluidigm Board, having served in multiple senior executive roles in the biopharmaceutical, life science tools, and molecular diagnostics sectors. He previously served as President and CEO of Biotheranostics, a privately held molecular diagnostics company, from 2014 until February 2017. Just prior to that, he served as President of Global Commercial Operations at Life Technologies, a $4 billion life science industry leader that was acquired by Thermo Fisher Scientific in 2014. Prior to that position, he led the $850 million Cell Systems Division for five years at Life Technologies. Before Life Technologies, Barthelemy was with Biogen for eight years in operational and commercial roles of increasing responsibility, including Vice President of Manufacturing. He began his career with Merck & Co., Inc. as a Project Engineer in the Vaccine Division. Barthelemy currently also serves on the Board of Directors of Repligen Corporation and he was on the Board of Essen BioScience, a privately held life science company, until its recent acquisition by Sartorius AG. He received an M.S. in chemical engineering from the University of California, Berkeley, and an engineering degree from Ecole Supérieure de Physique et de Chimie Industrielles in Paris.
“I am very excited to be joining Fluidigm at a critical juncture in its history,” said Barthelemy. “Fluidigm is in the middle of a business transformation that requires balancing investments in innovation, commercial execution, and operational excellence. I share their enthusiasm for building the next generation of automated mass cytometry and genomics workflow solutions for life science and clinical markets. I see tremendous potential in both areas.”
Dr. Paya brings to the Board over 15 years of senior executive experience in the large, mid-cap, and small-cap biopharmaceutical industries, combined with a prolific scientific background and a track record of leading high-impact innovation. Dr. Paya currently serves as President, Chief Executive Officer, and Director of Immune Design Corp., a clinical-stage immunotherapy company focused on oncology. He previously served as President of Elan Corporation, a pharmaceutical corporation later acquired by Perrigo Company, from 2008 to 2011. Before joining Elan Corporation, Dr. Paya was at Eli Lilly & Company from 2001 to 2008 as Vice President of Lilly Research Laboratories. From 1991 to 2001, Dr. Paya was Professor of Medicine, Immunology, and Pathology and Vice Dean of the Clinical Investigation Program at the Mayo Clinic in Rochester, Minnesota. He received his M.D. and Ph.D. degrees from the University of Madrid and underwent postdoctoral training at the Institute Pasteur in Paris.
“Fluidigm has breakthrough technologies that will shape how scientific discoveries are developed and applied to human health,” said Dr. Paya. “Joining a company with such a wide portfolio of industry-leading tools and a passion to innovate is a rare opportunity. In particular, I believe I can help them execute in a manner that reflects the business and scientific needs of oncology.”
“We are thrilled to welcome both Nicolas and Carlos to the Fluidigm Board of Directors,” said Christopher Linthwaite, President and CEO of Fluidigm. “Nicolas has a strong track record in driving sustainable growth and business turnarounds. His deep expertise in commercial and operational success in the life sciences industry is particularly relevant to our organizational goals. Carlos is a seasoned CEO, executive leader and world-class researcher with expertise in immunology and oncology. His academic and industrial experiences in these disease research areas are invaluable as we continue to innovate for these high-impact markets. Both of these new members will be instrumental in helping us accelerate several key elements of our business strategy and position the Fluidigm business for long-term success.”
Fluidigm (NASDAQ:FLDM) develops, manufactures, and markets life science analytical and preparatory systems for markets such as mass cytometry, high-throughput genomics, and single-cell genomics. We sell to leading academic institutions, clinical research laboratories, and pharmaceutical, biotechnology, and agricultural biotechnology companies worldwide. Our systems are based on proprietary microfluidics and multiparameter mass cytometry technology and are designed to significantly simplify experimental workflow, increase throughput, and reduce costs while providing excellent data quality. Fluidigm products are provided for Research Use Only. Not for use in diagnostic procedures.
We use our website (www.fluidigm.com), corporate Twitter account (@fluidigm), Facebook page (https://www.facebook.com/fluidigm), and LinkedIn page (https://www.linkedin.com/company/fluidigm-corporation) as channels of distribution of information about our products, our planned financial and other announcements, our attendance at upcoming investor and industry conferences, and other matters. Such information may be deemed material information, and we may use these channels to comply with our disclosure obligations under Regulation FD. Therefore, investors should monitor our website and our social media accounts in addition to following our press releases, SEC filings, public conference calls, and webcasts.
Fluidigm and the Fluidigm logo are registered trademarks of Fluidigm Corporation.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, among others, statements regarding changes in operations, development of next-generation products, and the ability of management personnel and our board of directors to contribute to the growth of Fluidigm’s business. These statements involve known and unknown risks, uncertainties, and other factors that may cause actual results to be materially different from any future results expressed or implied by these forward-looking statements, including (among others) risks relating to research and development activities and the growth of new and developing markets, Fluidigm’s ability to successfully launch new products and applications, and competition in Fluidigm’s primary markets. Information on these and additional risks, uncertainties, and other information affecting Fluidigm business and operating results are contained in Fluidigm’s Annual Report on Form 10-K for the year ended December 31, 2016, and in its other filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Fluidigm disclaims any obligation to update these forward-looking statements except as may be required by law.
Contact: Fluidigm Corporation Michaeline Bunting Sr. Director, Marketing Fluidigm Corporation 650 737 4190 firstname.lastname@example.org